Misplaced Pages

Atumelnant: Difference between revisions

Article snapshot taken from[REDACTED] with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 09:24, 27 December 2024 editGraeme Bartlett (talk | contribs)Administrators250,168 edits removed Category:Amides; added Category:Carboxamides using HotCat← Previous edit Latest revision as of 07:18, 9 January 2025 edit undoAlyInWikiWonderland (talk | contribs)Autopatrolled, Extended confirmed users83,368 edits No longer an orphan. 
(3 intermediate revisions by 3 users not shown)
Line 18: Line 18:
| widthR = | widthR =
| altR = | altR =
| captionLR = | captionLR =


<!-- Clinical data --> <!-- Clinical data -->
Line 39: Line 39:
| ATC_prefix = | ATC_prefix =
| ATC_suffix = | ATC_suffix =
| ATC_supplemental = | ATC_supplemental =


<!-- Legal status --> <!-- Legal status -->
Line 60: Line 60:
| legal_UN = | legal_UN =
| legal_UN_comment = | legal_UN_comment =
| legal_status = | legal_status =


<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
Line 70: Line 70:
| elimination_half-life = | elimination_half-life =
| duration_of_action= | duration_of_action=
| excretion = | excretion =


<!-- Identifiers --> <!-- Identifiers -->
Line 109: Line 109:
}} }}


'''Atumelnant''' (CRN04894) is an ] developed by Crinetics Pharmaceuticals for the treatment of ] (ACTH)-dependent endocrine disorders. It is a selective ] of the ] (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands.<ref>{{cite web | title = Atumelnant (CRN04894) | url = https://crinetics.com/pipeline/atumelnant-cushings-syndrome-cah/ | work = crinetics.com }}</ref> Atumelnant is being evaluated to treat conditions such as ] (CAH) and ACTH-dependent ] caused for example by ].<ref name="Varlamov_2024">{{cite journal | vauthors = Varlamov EV, Gheorghiu ML, Fleseriu M | title = Pharmacological management of pituitary adenomas - what is new on the horizon? | journal = Expert Opinion on Pharmacotherapy | volume = | issue = | pages = | date = December 2024 | pmid = 39718553 | doi = 10.1080/14656566.2024.2446625 }}</ref> '''Atumelnant''' (developmental code name '''CRN04894''') is an ] developed by Crinetics Pharmaceuticals for the treatment of ] (ACTH)-dependent ]s. It is a ] ] of the ] (MC2R), also known as the ACTH receptor, which is primarily expressed in the ]s.<ref>{{cite web | title = Atumelnant (CRN04894) | url = https://crinetics.com/pipeline/atumelnant-cushings-syndrome-cah/ | work = crinetics.com | date = 14 August 2020 }}</ref> Atumelnant is being evaluated to treat conditions such as ] (CAH) and ACTH-dependent ] caused for example by ].<ref name="Varlamov_2024">{{cite journal | vauthors = Varlamov EV, Gheorghiu ML, Fleseriu M | title = Pharmacological management of pituitary adenomas - what is new on the horizon? | journal = Expert Opinion on Pharmacotherapy | volume = | issue = | pages = | date = December 2024 | pmid = 39718553 | doi = 10.1080/14656566.2024.2446625 }}</ref>


== References == == References ==
{{reflist}} {{reflist}}



⚫ {{pharma-stub}}
{{Melanocortin receptor modulators}}

] ]
] ]
] ]
⚫ ]
]
] ]
] ]
Line 123: Line 127:
] ]
] ]

⚫ ]

⚫ {{pharma-stub}}

Latest revision as of 07:18, 9 January 2025

Pharmaceutical compound
Atumelnant
Clinical data
Other namesCRN04894
Identifiers
IUPAC name
  • N-octan-3-yl]-6-(2-ethoxyphenyl)-3-piperazin-1-yl]pyridine-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
UNII
Chemical and physical data
FormulaC33H42F3N5O3
Molar mass613.726 g·mol
3D model (JSmol)
SMILES
  • CC1CN(CCN1C2=C(N=C(C=C2)C3=CC=CC=C3OCC)C(=O)N4CN5CCC4CC5)C(=O)C6(CCC6)C(F)(F)F
InChI
  • InChI=InChI=1S/C33H42F3N5O3/c1-3-23-20-40(31(43)32(14-7-15-32)33(34,35)36)18-19-41(23)27-11-10-25(24-8-5-6-9-28(24)44-4-2)37-29(27)30(42)38-26-21-39-16-12-22(26)13-17-39/h5-6,8-11,22-23,26H,3-4,7,12-21H2,1-2H3,(H,38,42)/t23-,26-/m1/s1
  • Key:QJRFBKYETDVAJQ-ZEQKJWHPSA-N

Atumelnant (developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders. It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also known as the ACTH receptor, which is primarily expressed in the adrenal glands. Atumelnant is being evaluated to treat conditions such as congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing's syndrome caused for example by pituitary adenomas.

References

  1. "Atumelnant (CRN04894)". crinetics.com. 14 August 2020.
  2. Varlamov EV, Gheorghiu ML, Fleseriu M (December 2024). "Pharmacological management of pituitary adenomas - what is new on the horizon?". Expert Opinion on Pharmacotherapy. doi:10.1080/14656566.2024.2446625. PMID 39718553.


Melanocortin receptor modulators
MC1
MC2
MC3
MC4
MC5
Unsorted
Others


Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Atumelnant: Difference between revisions Add topic